Alder Biopharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Alder Biopharmaceuticals's estimated revenue is currently $41.1M per year.
- Alder Biopharmaceuticals received $287.5M in venture funding in February 2018.
- Alder Biopharmaceuticals's estimated revenue per employee is $144630
- Alder Biopharmaceuticals's total funding is $525M.
- Alder Biopharmaceuticals has 284 Employees.
- Alder Biopharmaceuticals grew their employee count by 19% last year.
- Alder Biopharmaceuticals currently has 5 job openings.
|Randall Schatzman||President and CEO|
|John Latham||Chief Scientific Officer|
|Jeffrey Smith||Managing Director|
|Elisabeth Sandoval||Chief Commercial Officer and EVP Corporate Strategy|
|Angela Willis||Vice President, Market Access|
|Shannon Carstens||Associate Director, QA Compliance|
|Larry Benedict||Executive Vice President and Principal Accounting Officer|
|Hassan Madani||Director, CMC Commercialization|
|Dario Gobunquin||Assoc. Director of Finance|
|Kate Cernok||Director, Medical Communications|
What Is Alder Biopharmaceuticals?
Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Alpine Immune S...||$6.8M||56||19%||$52.6M|
|Global Medical ...||$6.2M||43||10%|
Alder Biopharmaceuticals News
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society.
BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on ...
BOTHELL, Wash., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on ...
Alder Biopharmaceuticals Funding
|2008-01-14||$40.0M||C||TPG Biotech, Delphi Ventures||Article|
|2017-07-14||$172.5M||Undisclosed||Leerink Partners LLC||Article|
|2018-01-09||$100.0M||Undisclosed||Redmile Group LLC||Article|
|2018-01-30||$230.0M||Undisclosed||Goldman Sachs & Co. LLC,||Article|
|2018-02-05||$287.5M||Undisclosed||Goldman Sachs & Co. LLC,||Article|
Alder Biopharmaceuticals Executive Hires
|2009-08-13||Mark Young||SVP Pharmaceutical Operations||Article|
|2016-06-07||Roger K. Cady||VP neurology||Article|
|2016-06-30||Timothy M. Whitaker||Chief Medical Officer||Article|
|2016-09-07||Elisabeth A. Sandoval||Chief Commercial Officer||Article|
|2016-09-22||Nancy L. Boman||SVP Regulatory Affairs/Pharmacovigilance||Article|
|2016-10-12||Larry Benedict||EVP/Principal Accounting Officer||Article|
|2018-03-21||Paul Cleveland||Interim President & CEO||Article|
|2018-04-17||Erin Lavelle||Chief Operating Officer||Article|
|2018-04-24||Eric Carter||Interim Chief Medical Officer||Article|
|2019-01-18||Paul Streck||chief medical officer||Article|